Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
Rhea-AI Summary
Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, has scheduled its Q1 2025 earnings conference call and webcast for May 13, 2025, at 4:30 p.m. ET. The company will discuss financial results for the quarter ending March 31, 2025, and provide corporate updates.
Participants can join via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) using conference ID: VERRICA. The webcast will be accessible through Verrica's investor relations website and will remain archived for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, VRCA declined 9.20%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When is Verrica Pharmaceuticals (VRCA) reporting Q1 2025 earnings?
How can I listen to Verrica Pharmaceuticals' Q1 2025 earnings call?
How long will Verrica Pharmaceuticals' Q1 2025 earnings webcast be available?
What will be discussed in Verrica Pharmaceuticals' upcoming earnings call?
